| Title |
Trimethoprim–sulfamethoxazole therapy for patients with carbapenemase-producing Klebsiella pneumoniae infections: retrospective single-center case series
|
|---|---|
| Published in |
Infection, February 2017
|
| DOI | 10.1007/s15010-016-0968-x |
| Pubmed ID | |
| Authors |
Rita Murri, Barbara Fiori, Teresa Spanu, Ilaria Mastrorosa, Francesca Giovannenze, Francesco Taccari, Claudia Palazzolo, Giancarlo Scoppettuolo, Giulio Ventura, Maurizio Sanguinetti, Roberto Cauda, Massimo Fantoni |
| Abstract |
The objective of the study was to evaluate the efficacy and tolerability of trimethoprim-sulfamethoxazole (also known as co-trimoxazole, TMPS) to treat Klebsiella pneumoniae (Kp)-K. pneumoniae carbapenemase (KPC) infections. Clinical data of patients with a TMPS-susceptible Kp-KPC infection were collected as a case series. We report clinical outcomes and tolerability for 14 patients infected by Kp-KPC strains susceptible to TMPS, including three bloodstream infections. In ten cases (71.4%), TMPS was administered as monotherapy. In all but one case, Kp-KPC infection was cured. In the remaining patient, therapy was discontinued because of an adverse event. The use of TMPS to treat TMPS-susceptible Kp-KPC infections seems promising. |
X Demographics
The data shown below were collected from the profiles of 16 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 13% |
| Spain | 2 | 13% |
| Mexico | 1 | 6% |
| Brazil | 1 | 6% |
| Saudi Arabia | 1 | 6% |
| Bangladesh | 1 | 6% |
| Unknown | 8 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 10 | 63% |
| Practitioners (doctors, other healthcare professionals) | 4 | 25% |
| Scientists | 2 | 13% |
Mendeley readers
The data shown below were compiled from readership statistics for 42 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 1 | 2% |
| Unknown | 41 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 7 | 17% |
| Student > Postgraduate | 6 | 14% |
| Student > Master | 6 | 14% |
| Student > Doctoral Student | 3 | 7% |
| Other | 3 | 7% |
| Other | 10 | 24% |
| Unknown | 7 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 14 | 33% |
| Immunology and Microbiology | 7 | 17% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 10% |
| Biochemistry, Genetics and Molecular Biology | 3 | 7% |
| Agricultural and Biological Sciences | 2 | 5% |
| Other | 2 | 5% |
| Unknown | 10 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 August 2023.
All research outputs
#3,391,552
of 24,224,854 outputs
Outputs from Infection
#176
of 1,502 outputs
Outputs of similar age
#69,731
of 427,943 outputs
Outputs of similar age from Infection
#2
of 19 outputs
Altmetric has tracked 24,224,854 research outputs across all sources so far. Compared to these this one has done well and is in the 85th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,502 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.3. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 427,943 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 83% of its contemporaries.
We're also able to compare this research output to 19 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.